Overview

Semaglutide in CFRD

Status:
Not yet recruiting

Trial end date:
2025-12-31

Target enrollment:

Participant gender:

Summary

This open label, single arm pilot study, will examine the safety and tolerability of GLP-1RA semaglutide as an add-on therapy to insulin for overweight/obese adult patients with cystic fibrosis related diabetes (CFRD).

Phase:

Phase 2/Phase 3

Details

Lead Sponsor:

Amir Moheet

Collaborator:

Cystic Fibrosis Foundation